Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. 2006

Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
Hepatic Hemodynamic Laboratory, VA Medical Center, West Haven, CT 06516, USA.

OBJECTIVE Cirrhotic livers have a deficient vasodilator response to nitric oxide (NO). The vasodilator effect of NO is normally limited by the degradation of its second messenger cyclic guanosine 3', 5' monophosphate by phosphodiesterases. We investigated (1) the phosphodiesterase-5 (PDE-5) expression in normal and cirrhotic rat livers, (2) the location of the deficient response to NO in cirrhotic livers, and (3) the effect of the PDE-5 inhibitor Sildenafil citrate on this deficient response. METHODS Normal and ascitic cirrhotic rats were subjected to liver perfusion with continuous measurement of both perfusion and sinusoidal (wedge hepatic) pressures. After incubation with N-monomethyl-l-arginine and pre-constriction with Methoxamine, concentration-response curves to the spontaneous NO donor S-nitroso-N-acetylpenicillamine were obtained in the absence or presence of Sildenafil (10(-8)M). RESULTS PDE-5 expression (Western blot) in cirrhotic livers was higher than in normal livers (P=0.042). Compared to normal livers, cirrhotic livers showed a decreased response to S-nitroso-N-acetylpenicillamine in the pre-sinusoidal area (P=0.003) but not in the sinusoidal/post-sinusoidal area (P=0.433). In the presence of Sildenafil, normal and cirrhotic livers showed similar pre-sinusoidal (P=0.419) and sinusoidal/post-sinusoidal (P=0.875) responses to S-nitroso-N-acetylpenicillamine. CONCLUSIONS Increased PDE-5 expression is involved in the decreased vascular response to NO in cirrhotic livers.

UI MeSH Term Description Entries
D008102 Liver Circulation The circulation of BLOOD through the LIVER. Hepatic Circulation,Circulation, Liver,Circulation, Hepatic
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D010727 Phosphoric Diester Hydrolases A class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. EC 3.1.4. Phosphodiesterase,Phosphodiesterases,Hydrolases, Phosphoric Diester
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000068677 Sildenafil Citrate A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION. 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate,Acetildenafil,Desmethyl Sildenafil,Desmethylsildenafil,Homosildenafil,Hydroxyhomosildenafil,NCX-911,Revatio,Sildenafil,Sildenafil Lactate,Sildenafil Nitrate,UK 92480-10,UK-92,480-10,Viagra,Citrate, Sildenafil,Lactate, Sildenafil,NCX 911,NCX911,Nitrate, Sildenafil,Sildenafil, Desmethyl,UK 92,480 10,UK 92480 10,UK 9248010

Related Publications

Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
April 2008, Hepatology (Baltimore, Md.),
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
August 2002, Hepatology (Baltimore, Md.),
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
October 1997, Hypertension (Dallas, Tex. : 1979),
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
October 2010, American journal of physiology. Renal physiology,
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
March 1998, Gastroenterology,
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
April 2003, American journal of physiology. Gastrointestinal and liver physiology,
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
January 1999, Life sciences,
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
April 1999, Journal of cardiovascular pharmacology,
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
January 1996, Hepatology (Baltimore, Md.),
Mauricio R Loureiro-Silva, and Yasuko Iwakiri, and Juan G Abraldes, and Omar Haq, and Roberto J Groszmann
July 2004, World journal of gastroenterology,
Copied contents to your clipboard!